Pharmacogenetic testing, which is used to classify how patients with major depressive disorder (MDD) metabolize medications, reduces adverse drug-gene interactions, new research shows. In a randomized ...

Patients with MDD exhibit significantly higher triglyceride levels, which correlate with worse functional impairment scores.

Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies that included 3,532 ...

Anti-inflammatory therapies that are highly effective for inflammatory skin diseases might also be relevant to depression because of shared inflammatory pathways.

Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations in ...

Neuropsychiatric drug development is rife with clinical trial failures, but Alto Neuroscience aims to overcome these hurdles with a precision medicine approach that matches a patient to a drug. A ...